Botanix Investor Centre

Botanix Pharmaceuticals is a clinical stage synthetic cannabinoid pharmaceutical company with a targeted pipeline of dermatology and antimicrobial products. Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach. Our shareholders are valued partners in our Company, so we invite you to explore our Investor Centre, subscribe to our email updates and we will keep you updated with our progress.

Share price


Change

December 9, 2019
September 17, 2019
January 31, 2019
November 15, 2018
August 13, 2018
April 9, 2018
November 13, 2017

Latest video

‘Superbugs’ a far greater risk than Covid in the Pacific, scientist warns

The emergence of antimicrobial resistance (AMR), including drug-resistant…

Experts Say Humans Are Living in an ‘Age of Pandemics’—and COVID Won’t Be the Last

Experts have warned that the COVID-19 pandemic might just be…

Botanix’s BTX 1801 proven to kill superbugs

Cannabinoid skincare company Botanix (BOT) has proven its BTX…

New antimicrobial data and conference presentation

Botanix Pharmaceuticals (ASX:BOT) has today shared a market…

NEW DATA | Time lapse videos – S.aureus treated with synthetic cannabidiol

Botanix Pharmaceuticals released promising new clinical data…

The marketplace for new antibiotics is fundamentally broken

One of the mysteries of COVID-19 is why it kills some patients…

Drug study will use synthetic cannabidiol to fight antimicrobial resistance

Addressing antimicrobial resistance is a pressing priority for…

Could Drug-Resistant Bacteria Cause The Next Pandemic?

As humanity tallies the growing cost of Covid-19 in lives and…

Interested in investing? Check out our latest investor presentation.

Sign up to receive our latest news.

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere